Page 3 - Smartpharm Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Smartpharm therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Smartpharm Therapeutics Today - Breaking & Trending Today

Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein

Share:
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) Sorrento Therapeutics, Inc. (NASDAQ:SRNE, , Sorrento , )), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation surveillance program for its neutralizing antibodies currently in clinical and pre-clinical development for treatment of patients with COVID-19 disease.
Dr. Robert Allen, Senior Vice President, Antiviral and Oncolytic Immunotherapy Development at Sorrento and Chief Scientific Officer of SmartPharm Therapeutics, will be presenting data from the SARS-CoV-2 Spike protein variant screening program at PepTalk 2021 today and on Thursday of this week.
January 19, 2021 at 1:25 PM PST
A Novel Low-Immunogenic DNA Plasmid Encoded with a Therapeutic Antibody for Long-Lasting Expression ....

South Africa , United States , United Kingdom , Alexis Nahama , Robert Allen , Semnur Pharmaceuticals Inc , Phage Library , Exchange Commission , Sorrento Therapeutics Inc , Corporate Development , Scilex Pharmaceuticals Inc , Oncolytic Immunotherapy Development At Sorrento , Senior Vice President , Chief Scientific Officer , Smartpharm Therapeutics , Novel Low Immunogenic , Therapeutic Antibody , Long Lasting Expression , Sorrento Therapeutics , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Semnur Pharmaceuticals , Scilex Pharmaceuticals , All Rights , ஒன்றுபட்டது மாநிலங்களில் ,

Sorrento Therapeutics developing antibodies injection and nose drops to fight Covid-19

Sorrento Therapeutics developing antibodies injection and nose drops to fight Covid-19
CNBC
12/23/2020
Sorrento Therapeutics is working on new antibody therapeutics in the fight against Covid-19.
It won a $34 million contract from DARPA co-funded by JPEO to develop an intramuscular injection that delivers gene-encoded neutralizing antibodies against Covid-19 and its variant strains.
The company filed an investigational new drug application with the FDA for a Phase 1 clinical trial to test the safety and efficacy of COVI-DROPS, antibody nose drops that it claims boosts immunity against Covid-19 by blocking the infection and spread of the virus.
© Provided by CNBC
Medical staff member Christina Mathers attends to a patient, who is unconscious, as she holds the patient s hand in the COVID-19 intensive care unit (ICU) at the United Memorial Medical Center on December 21, 2020 in Houston, Texas. ....

United States , San Diego , University Of Texas , Moncef Slaoui , Henry Ji , Donald Trump , Christina Mathers , Eli Lilly , Slobodan Paessler , Healthcare Technologies Institute , Animal Biosafety Laboratory , United Memorial Medical Center On , University Of Birmingham , University Of Texas Medical Branch , John Hopkins University , University Of Pennsylvania , Sorrento Therapeutics , United Memorial Medical Center , Smartpharm Therapeutics , Texas Medical Branch , John Hopkins , Chief Executive Officer , Operation Warp Speed , Auris Medical , President Donald , ஒன்றுபட்டது மாநிலங்களில் ,

Sorrento Up on Request for Emergency Authorization for Covid Test

Sorrento Up on Request for Emergency Authorization for Covid Test
Sorrento Therapeutics jumped after the biopharma said it applied for FDA emergency-use authorization for its covid-19 test.
Author:
Sorrento Therapeutics (
SRNE) - Get Report shares jumped after the biopharma said it had applied to the Food and Drug Administration for emergency-use authorization for its covid-19 test.
The stock recently traded at $8.80, up 22%. It had well more than doubled year to date amid optimism about its covid efforts.
The test is called Covi-Stix. “In testing conducted to date, Covi-Stix has provided results within 15 minutes, with positive detection as quickly as two minutes for patient samples with high viral load,” Sorrento said in a statement. ....

Smartpharm Sorrento , Defense Advanced Research Projects Agency , Drug Administration , Nuclear Defense , Program Executive Office For Chemical , Sorrento Therapeutics , Smartpharm Therapeutics , Joint Program Executive Office , அணு பாதுகாப்பு , ப்ரோக்ர்யாம் நிர்வாகி அலுவலகம் க்கு இரசாயன , ஸாரெஂடோ சிகிச்சை , கூட்டு ப்ரோக்ர்யாம் நிர்வாகி அலுவலகம் ,